Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Calreticulin
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Role in cancer == Calreticulin (CRT) is expressed in many cancer cells and plays a role to promote [[macrophage]]s to engulf hazardous cancerous cells. The reason why most of the cells are not destroyed is the presence of another molecule with signal [[CD47]], which blocks CRT. Hence antibodies that block CD47 might be useful as a cancer treatment. In mice models of [[myeloid leukemia]] and [[non-Hodgkin lymphoma]], anti-CD47 were effective in clearing cancer cells while normal cells were unaffected.<ref name="pmid21178137">{{cite journal | vauthors = Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL | title = Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47 | journal = Science Translational Medicine | volume = 2 | issue = 63 | pages = 63ra94 | date = Dec 2010 | pmid = 21178137 | pmc = 4126904 | doi = 10.1126/scitranslmed.3001375}} *{{cite web |author=Christopher Vaughan |date=December 22, 2010 |title=Many cancer cells found to have an 'eat me' signal in study |website=Stanford School of Medicine |url=http://med.stanford.edu/ism/2010/december/crt-signal.html |archive-url=https://web.archive.org/web/20131016145928/http://med.stanford.edu/ism/2010/december/crt-signal.html |archive-date=2013-10-16}}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)